TIVDAK ( tisotumab vedotin - tftv ) Significantly Prolonged
The latest results from a global trial of cervical cancer therapy have shown significant reductions in the risk of death in recurrent or metastatic cancer (STI) patients, according to preliminary results released by the US regulatory agency (ESMO).
Source: globenewswire.comPublished on 2023-10-22
Related news
- Canadian Solar Subsidiary CSI Solar Updated IPO Prospectus and Indicative IPO Timetable Published by the Shanghai Stock Exchange
- Gold Royalty to Expand Existing Secured Revolving Credit Facility Up to US$35 Million and Joins United Nations Global Compact
- Molecular Partners Reports H1 2023 Corporate Highlights and Financials
- Canadian Solar Signs 381 MWp Solar Corporate PPA in Brazil
- Financial institutions general regulatory news , February 2021 # 3 | Hogan Lovells
- Qatar and France : Fifty years of advantageous friendship
- Flywire Corporation ( NASDAQ : FLYW ) Q4 2022 Earnings Call Transcript
- K2 INTEGRITY ANNOUNCES EXPANSION OF ESG CERTIFICATION SOLUTION
- Retailers In the Dark on Consumer Sustainability Sentiment ...
- Investegate | Company Announcement
- Infosys Foundation united states Announces Crossroads 2023 Conference in Tempe , AZ
- MSCI 2023 Market Classification Review
- Nokia and Apple sign long - term patent license agreement
- Infosys Recognized as Global Top Employer for the Second Consecutive Year ; Ranked # 1 in India Again
- GENFITReports First Half - Year 2023 Financial Results and Provides Corporate Update